Recruitment evaluation of a gerotherapeutic randomized controlled trial testing alpha-ketoglutarate in biologically older, middle-aged adults (ABLE).

Zhi Meng Lim, Yi Ern Chew, Lihuan Guan, Weilan Wang, Muhammad Daniel A Mahadzir, Rajkumar Dorajoo, Brian Kennedy, Elena Sandalova, Andrea B Maier

Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Centre for Healthy Longevity, National University Health System (NUHS), Singapore.Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Centre for Healthy Longevity, National University Health System (NUHS), Singapore. · pubmed

Paper

Abstract

Gerotherapeutic interventions that optimize the health and healthspan of biologically older, yet generally healthy adults are importance for reducing healthcare costs associated with ageing populations. It remains unclear whether recruiting middle-aged individuals with an older biological age is feasible in gerotherapeutic trials. The aim is to evaluate feasibility of recruiting biologically older yet generally healthy middle-aged adults for Alpha-ketoglutarate Supplementation and BiologicaL agE in middle-aged adults (ABLE) trial.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper aims to evaluate the feasibility of recruiting biologically older middle-aged adults for a trial testing alpha-ketoglutarate supplementation. This research is relevant as it explores a potential gerotherapeutic intervention that could optimize healthspan and address the biological aspects of aging.

Author of this paper? Send a correction.